Business Wire

MA-PRECISELY

Share
Etam Group Relies on Precisely Automate to Drive Business Agility and Innovation

Precisely, the global leader in data integrity, today announced that Etam Group, a major international retailer and leading lingerie brand in France, has implemented its Automate Studio solution across all subsidiaries to support company-wide accounts payable processes. By providing seamless SAP data access to decision-makers in real-time, Automate Studio (formerly Winshuttle Studio) enables Etam’s accounting teams to work autonomously without support from IT personnel, reduce operational costs, and drive greater innovation across the organization.

Business agility is critical in the retail industry, with companies seeking to balance tight margins with the need to innovate and stay competitive. With more pressure than ever to optimize margins through existing operating structures and processes, it comes as no surprise that automation has emerged as a top consideration for retailers in 2024. Retail companies are increasingly seeing the need to simplify and accelerate processes across their major functions to drive business efficiencies, improve customer experience, and stay compliant with an ever-changing regulatory landscape.

“In the retail sector, businesses must stay agile and be able to implement ideas quickly, something which is also incredibly important in accounting,” said Stéphane Delattre, Vice President – Accounting for Europe at Etam Group. “Automate Studio increases our productivity and efficiency, enabling mass data simplification and empowering decision-makers to access trustworthy data in real-time. We call it the ‘miracle product’!”

The Etam Group has an impressive history of driving innovation to optimize infrastructure and provide great customer experience – having invented the concept of just-in-time automatic restocking in 1965. But with presence now in over 1,500 stores located across 57 countries, the retailer needed a solution that would work with its SAP ERP (enterprise resource planning) software and support all the company’s subsidiaries in streamlining their data management.

Automate Studio is the premier Excel-to-SAP solutions platform that enables business users to automate complex SAP business processes and make mass data changes quickly and easily. The platform allows customers to eliminate manual data entries and upload and download SAP data in record time, while simultaneously improving data quality. Automate Studio empowers business teams by reducing their reliance on IT support for automating Excel to SAP processes. Now citizen developers within business teams can create and manage their own solutions faster, while ensuring compliance and security standards are maintained.

“Before we deployed Automate Studio, we manually handled hundreds of invoices a month which could be very time-consuming,” said Delattre. “This practical solution from Precisely has not only increased our internal productivity but has helped us save time. Previously, one invoice took three minutes to create and now Automate Studio facilitates the creation of nearly 600 invoices within 15 minutes. Another example is how drastically it reduced the time needed to add purchasing conditions to orders in SAP – this used to take two days but can now be completed in just two hours.”

“Precisely is committed to helping customers automate their SAP processes to maintain agility, accelerate speed of business, and build the integrity of their data,” said Pat McCarthy, Chief Revenue Officer at Precisely. “As more organizations embark on digital transformation across their core functions, they are realizing the power of process automation, fueled by accurate, consistent, and contextual data to help ensure success.”

Learn more about Precisely Automate Studio.

About Etam Group

One hundred years old, still family-owned and independent, the Etam Group, now a leader in France and internationally, is a key player in innovative and creative lingerie and fashion. With its identity and historical know-how, the Etam Group cultivates this unique relationship with its customers through its brands Etam, Maison 123, Undiz Livy and Ysé, and a strong omnichannel presence based on more than 1500 stores in 57 countries. Learn more at https://etam-groupe.com

About Precisely

Precisely is the global leader in data integrity, providing accuracy, consistency, and context in data for 12,000 customers in more than 100 countries, including 99 of the Fortune 100. Precisely’s data integration, data quality, data governance, location intelligence, and data enrichment products power better business decisions to create better outcomes. Learn more at www.precisely.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240228517820/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye